Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.

ABSTRACT:

Background

Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd -generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards reversible and irreversible EGFR TKI.

Methods

Rebiopsies of patients after progression to EGFR TKI therapy (> 6 months) were targeted to histological and molecular analysis. Multiplexed targeted sequencing (NGS) was conducted to identify acquired resistance mutations (e.g. EGFR p.T790M). Further, Fluorescence in situ hybridisation (FISH) was applied to investigate the status o

SUBMITTER: Wagener-Ryczek S 

PROVIDER: S-EPMC7216404 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature